137 related articles for article (PubMed ID: 21084244)
1. [Genetic and molecular abnormalities of glioblastomas (GBM)].
Larsen C
Bull Cancer; 2010 Nov; 97(11):1389-407. PubMed ID: 21084244
[TBL] [Abstract][Full Text] [Related]
2. Radiation-induced extracellular vesicle (EV) release of miR-603 promotes IGF1-mediated stem cell state in glioblastomas.
Ramakrishnan V; Xu B; Akers J; Nguyen T; Ma J; Dhawan S; Ning J; Mao Y; Hua W; Kokkoli E; Furnari F; Carter BS; Chen CC
EBioMedicine; 2020 May; 55():102736. PubMed ID: 32361246
[TBL] [Abstract][Full Text] [Related]
3. Association between glioblastoma cell-derived vessels and poor prognosis of the patients.
Mei X; Chen YS; Zhang QP; Chen FR; Xi SY; Long YK; Zhang J; Cai HP; Ke C; Wang J; Chen ZP
Cancer Commun (Lond); 2020 May; 40(5):211-221. PubMed ID: 32359215
[TBL] [Abstract][Full Text] [Related]
4. Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations.
Hartmann C; Hentschel B; Simon M; Westphal M; Schackert G; Tonn JC; Loeffler M; Reifenberger G; Pietsch T; von Deimling A; Weller M;
Clin Cancer Res; 2013 Sep; 19(18):5146-57. PubMed ID: 23918605
[TBL] [Abstract][Full Text] [Related]
5. Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation.
Kessler T; Sahm F; Sadik A; Stichel D; Hertenstein A; Reifenberger G; Zacher A; Sabel M; Tabatabai G; Steinbach J; Sure U; Krex D; Grosu AL; Bewerunge-Hudler M; Jones D; Pfister SM; Weller M; Opitz C; Bendszus M; von Deimling A; Platten M; Wick W
Neuro Oncol; 2018 Feb; 20(3):367-379. PubMed ID: 29016808
[TBL] [Abstract][Full Text] [Related]
6. [Epigenetic regulation in glioblastomas].
Quillien V
Ann Pathol; 2009 Nov; 29 Spec No 1():S34-6. PubMed ID: 19887247
[No Abstract] [Full Text] [Related]
7. The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas.
Juratli TA; Kirsch M; Geiger K; Klink B; Leipnitz E; Pinzer T; Soucek S; Schrock E; Schackert G; Krex D
J Neurooncol; 2012 Dec; 110(3):325-33. PubMed ID: 23015095
[TBL] [Abstract][Full Text] [Related]
8.
Arora I; Gurav M; Rumde R; Dhanavade S; Kadam V; Kurani H; Shetty O; Goda JS; Shetty P; Moiyadi A; Gupta T; Jalali R; Epari S
Neurol India; 2018; 66(4):1106-1114. PubMed ID: 30038102
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients.
Takahashi Y; Nakamura H; Makino K; Hide T; Muta D; Kamada H; Kuratsu J
World J Surg Oncol; 2013 Oct; 11():284. PubMed ID: 24160898
[TBL] [Abstract][Full Text] [Related]
10. Molecular neuro-oncology and the challenge of the blood-brain barrier.
Aiken R
Semin Oncol; 2014 Aug; 41(4):438-445. PubMed ID: 25173137
[TBL] [Abstract][Full Text] [Related]
11. IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry.
Yang P; Zhang W; Wang Y; Peng X; Chen B; Qiu X; Li G; Li S; Wu C; Yao K; Li W; Yan W; Li J; You Y; Chen CC; Jiang T
Oncotarget; 2015 Dec; 6(38):40896-906. PubMed ID: 26503470
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of MGMT promoter methylation and TP53 mutation in glioblastomas depends on IDH1 mutation.
Wang K; Wang YY; Ma J; Wang JF; Li SW; Jiang T; Dai JP
Asian Pac J Cancer Prev; 2014; 15(24):10893-8. PubMed ID: 25605197
[TBL] [Abstract][Full Text] [Related]
13. Genetic and epigenetic landscape of IDH-wildtype glioblastomas with FGFR3-TACC3 fusions.
Mata DA; Benhamida JK; Lin AL; Vanderbilt CM; Yang SR; Villafania LB; Ferguson DC; Jonsson P; Miller AM; Tabar V; Brennan CW; Moss NS; Sill M; Benayed R; Mellinghoff IK; Rosenblum MK; Arcila ME; Ladanyi M; Bale TA
Acta Neuropathol Commun; 2020 Nov; 8(1):186. PubMed ID: 33168106
[TBL] [Abstract][Full Text] [Related]
14. Molecular biology of glioblastoma: Classification and mutational locations.
Soomro SH; Ting LR; Qing YY; Ren M
J Pak Med Assoc; 2017 Sep; 67(9):1410-1414. PubMed ID: 28924284
[TBL] [Abstract][Full Text] [Related]
15. Molecular biology of high-grade gliomas: what should the clinician know?
Hofer S; Rushing E; Preusser M; Marosi C
Chin J Cancer; 2014 Jan; 33(1):4-7. PubMed ID: 24325789
[TBL] [Abstract][Full Text] [Related]
16. IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme.
Kalkan R; Atli Eİ; Özdemir M; Çiftçi E; Aydin HE; Artan S; Arslantaş A
Gene; 2015 Jan; 554(1):81-6. PubMed ID: 25455102
[TBL] [Abstract][Full Text] [Related]
17. Loss of 5-hydroxymethylcytosine and intratumoral heterogeneity as an epigenomic hallmark of glioblastoma.
Kraus TF; Kolck G; Greiner A; Schierl K; Guibourt V; Kretzschmar HA
Tumour Biol; 2015 Nov; 36(11):8439-46. PubMed ID: 26022161
[TBL] [Abstract][Full Text] [Related]
18. MGMT Promoter Methylation Status Is Not Related to Histological or Radiological Features in IDH Wild-type Glioblastomas.
Mikkelsen VE; Dai HY; Stensjøen AL; Berntsen EM; Salvesen Ø; Solheim O; Torp SH
J Neuropathol Exp Neurol; 2020 Aug; 79(8):855-862. PubMed ID: 32688383
[TBL] [Abstract][Full Text] [Related]
19. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A
Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882
[TBL] [Abstract][Full Text] [Related]
20. MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors.
Mellai M; Monzeglio O; Piazzi A; Caldera V; Annovazzi L; Cassoni P; Valente G; Cordera S; Mocellini C; Schiffer D
J Neurooncol; 2012 May; 107(3):617-31. PubMed ID: 22287028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
